Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
This item clarifies what constitutes the fee schedule for the Dividend Aristocrats Etf and how each fee contributes to total costs.
11,557 articlesA major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Britannica and Merriam-Webster filed a lawsuit against OpenAI, alleging unauthorized use of their content to train AI...
Pre-marketing for homes, dubbed coming soon listings, has moved from niche tests to a nationwide driver of housing de...
The Senate delivers a bipartisan win with the ROAD to Housing Act, yet observers say the measure only scratches the s...
With rate-cut bets disappearing, traders pivot to potential rate hikes and Bitcoin’s role as a long-term hedge agains...
As traditional markets wobble, smart investors are turning to carefully chosen cryptocurrencies. This guide reveals t...
Analysts see Elon Musk's Terafab strategy as a potential catalyst for chip-equipment makers and select chip stocks, b...
Investors often see a mixed day after defense-news headlines. This deep dive explains the kratos defense stock drop, ...
KB Home's Q1 2026 results shed light on the company’s earnings trajectory and the housing market dynamics. This guide...
Lucid Diagnostics (LUCD) is navigating reimbursement and adoption as it scales its non-invasive tests. This analysis ...
New York City is turning a neighborhood challenge into a funding opportunity. This guide explains how ADU grants and ...
When homes linger on the market, buyers gain negotiating power and lenders adjust terms. This guide explains how stal...